(Q36016233)

11 August 2017

1 reference

title

Response of low-grade oligodendroglial tumors to temozolomide (English)

1 reference

11 August 2017

1 reference

0 references

Thomas N Byrne

1

1 reference

11 August 2017

publication date

1 December 2004

1 reference

Journal of Neuro-Oncology

11 August 2017

published in

1 reference

11 August 2017

volume

70

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

279-280

1 reference

Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma

11 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-004-5896-4

Long-term outcome of low-grade oligodendroglioma and mixed glioma.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-004-5896-4

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

21 January 2018

1 reference

12 December 2020

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

1 reference

12 December 2020

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

1 reference

12 December 2020

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

1 reference

12 December 2020

Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities

1 reference

12 December 2020

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

1 reference

12 December 2020

Phase II trial of temozolomide in patients with progressive low-grade glioma

1 reference

12 December 2020

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

10.1007/S11060-004-5896-4

Identifiers

DOI

1 reference

11 August 2017

1 reference